Leveraging Real-World Data in COVID-19 Response-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Leveraging Real-World Data in COVID-19 Response

Published:2022-09-14 Issue: Volume: Page:1-14
ISSN:1946-6315
Container-title:Statistics in Biopharmaceutical Research
language:en
Short-container-title:Statistics in Biopharmaceutical Research

Author:

Cooner Freda¹,Liao Ran²^ORCID,Lin Junjing³^ORCID,Barthel Sophie⁴,Seifu Yodit⁵,Ruan Shiling⁶

Affiliation:

1. Amgen Inc., Thousand Oaks, CA;

2. Eli Lilly & Co, Lilly Corporate Center, Indianapolis, IN;

3. Takeda Pharmaceutical Co. Limited, Cambridge, MA;

4. PRA Health Science, Mannheim, Germany;

5. Merck & Co., Inc., Kenilworth, NJ;

6. Innovent Biologics, Inc., Rockville, MD

Publisher

Informa UK Limited

Subject

Pharmaceutical Science,Statistics and Probability

Link

https://www.tandfonline.com/doi/pdf/10.1080/19466315.2022.2096688

Reference100 articles.

1. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study

2. AHA COVID-19 CVD Registry (2021), available at https://www.heart.org/en/professional/quality-improvement/covid-19-cvd-registry. Accessed October 21, 2021.

3. How will country-based mitigation measures influence the course of the COVID-19 epidemic?

4. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19

5. ASCO Survey on COVID-19 in Oncology (ASCO) Registry (2021), available at https://www.asco.org/asco-coronavirus-information/coronavirus-registry. Accessed October 21, 2021.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP